Neil Versel is an editor at GenomeWeb. He covers the life science and healthcare informatics markets.
After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.
The company also reported that its Q3 revenue rose 93 percent to $83.2 million, beating the Wall Street consensus estimate.
Though nonbinding, the recent guidance provides clues on which types of clinical decision support software the FDA will treat like medical devices.
Aiforia offers a series of cancer-specific, CE-marked models and a DIY development platform for diagnostic and clinical decision support.
The privately held company is coupling gene expression tests with analysis to produce clinical decision support as it expands beyond its historic focus on pharma.
The Italian startup is expanding its eVai software platform to digenic rare disease diagnostics as it also broadens its marketing focus.
The molecular diagnostics and bioinformatics firm reduced its 2022 forecast as it reported a 23 percent year-over-year revenue decline in Q2.
The firm cited foreign currency weakness against the dollar in reducing its full-year estimate even as Q2 revenues grew 15 percent to $11.7 million.
The firm cited foreign currency weakness against the dollar in reducing its full-year estimate even as Q2 revenues grew 15 percent to $11.7M.
Although the firm remains in the red, the new CEO is counting on testing volume growth, health system partnerships, and operational efficiencies including layoffs to reach profitability.